ABUS vs BRO · P/E 5.4, rev $6.2M vs P/E 30, rev $4.80B
Arbutus Biopharma Corp (ABUS) versus Brown & Brown Inc (BRO) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Brown & Brown Inc (BRO) is a insurance brokers company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported BRO revenue for 2024-12-31 was $4.80B. Net income was $1.00B. Revenue was up 12.9% from 2023-12-31 to 2024-12-31. BRO currently screens at market cap $35.56B and trailing P/E 30.0.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. BRO currently screens at market cap $35.56B and trailing P/E 30.0.
Not investment advice. Open the ABUS and BRO stock pages for the full models.
Not investment advice.